Cardiovascular diseases, including coronary heart disease, stroke, and peripheral arterial disease, are the most prevalent conditions and leading causes of mortality, worldwide. In addition, age, sex, overweight, hypertension, smoking, and diabetes are widely accepted as major risk factors for the development of cardiovascular disease[@b1]. Furthermore, recent studies have reported that hyperuricaemia[@b2][@b3][@b4] and elevated levels of homocysteine[@b5][@b6] are also associated with cardiovascular disease, and a significant positive correlation has been observed between the serum concentrations of uric acid and homocysteine[@b7].

In addition to the above-mentioned factors, altered lipid metabolism, such as the disruption of cholesterol homeostasis via altered liver function, is another major risk factor for cardiovascular disease[@b8]. Cholesterol is a critical lipid that is a component of biological cell membranes and is an important precursor of steroid hormones and bile acids. Unfortunately, the disruption of cholesterol homeostasis significantly increases the risk of premature cardiovascular disease[@b9]. To monitor for this disruption, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) are among the most commonly used clinical biomarkers[@b10], with high LDL-C and low HDL-C levels indicating major risks for the development of coronary heart disease[@b11]. In addition, prospective studies investigating different racial and ethnic populations have confirmed that HDL-C is a strong, consistent, and independent predictive factor for the incidence of cardiovascular disease[@b10][@b12]. Furthermore, the Framingham study demonstrated that a combination of high LDL-C and low HDL-C levels is a strong predictor of the relative risk of cardiovascular events[@b13]. Moreover, the LDL-C/HDL-C ratio is a precise marker of cholesterol homeostasis, and can help predict cardiovascular events[@b14].

Previous genome-wide association studies have examined the genetic factors that control serum uric acid concentrations, and have identified 14 candidate causal single nucleotide polymorphisms (SNPs) and two pathways involving the *PKD2*, *SLC17A1*, *SLC17A3*, *SLC17A4*, and *SLC2A9* genes[@b15]. One of these genes (*SLC17A1*) encodes the solute carrier family 17 (organic anion transporter), member 1, which is also known as sodium phosphate transport protein 1. This protein is expressed in the sinusoidal membrane of hepatocytes and in the proximal tubules in the kidneys[@b16]; in the proximal tubules, it acts as a renal transporter of uric acid and mediates the co-transport of sodium and inorganic phosphate[@b17]. Additionally, *SLC17A1* SNPs are associated with kidney function indicators, such as suppressed serum uric levels and gout, in Japanese men[@b18]. Because hyperuricaemia is an undisputed and highly effective biomarker for predicting cardiovascular risk, *SLC17A1* SNPs might also suppress cardiovascular risk factors. However, whether *SLC17A1* SNPs, associated with liver function, are also associated with cardiovascular risk factors remains unknown. Cholesterol and homocysteine are both metabolised in the liver; therefore, we analysed three *SLC17A1* SNPs (rs1165196, rs1179086, and rs3757131) to evaluate their association with cholesterol homeostasis and homocysteine levels, and their roles as predictors of cardiovascular events. This analysis was conducted as a cross-sectional study using a large-scale pooled analysis of the Japanese general population.

Results
=======

Participant characteristics
---------------------------

[Table 1](#t1){ref-type="table"} shows the participants' characteristics, including their anthropometric measures, blood chemistry data, questionnaire responses, total energy and macronutrient intake, and distribution of the three polymorphisms according to sex. The mean age of the included men was 55.6 years, compared to 54.8 years for the women. Significant differences were not observed in comparisons of the metabolic equivalents (METs) and polymorphism allele frequency data between the men and women. Furthermore, the allele frequencies for the polymorphisms were similar to those in other Japanese populations[@b18], and were in agreement with the Hardy-Weinberg equilibrium (rs1165196 for men: χ^2^ = 0.571, p = 0.319; rs1165196 for women: χ^2^ = 1.241, p = 0.265; rs1179086 for men: χ^2^ = 0.023, p = 0.877; rs1179086 for women: χ^2^ = 1.350, p = 0.245; rs3757131 for men: χ^2^ = 0.284, p = 0.593; rs3757131 for women: χ^2^ = 1.053, p = 0.304).

Associations between polymorphisms and participant characteristics, according to sex
------------------------------------------------------------------------------------

The distributions of the three polymorphism genotypes are listed in [Tables 2](#t2){ref-type="table"}-[](#t3){ref-type="table"}[4](#t4){ref-type="table"}. For each genotype, the major homozygotes had significantly higher levels of uric acid, compared to the heterozygotes and minor homozygotes, in both sexes. Similarly, the major homozygous alleles in rs1165196 and rs3757131 exhibited high homocysteine and low folic acid levels in men. We also compared the major homozygotes with the heterozygotes and minor homozygotes. In men, rs1165196 and rs3757131 exhibited similar statistical significance. When compared to the major homozygous alleles, the combined minor genotype (TC + CC in rs1165196 and CT + TT in rs3757131) was associated with significantly higher folic acid levels, and significantly lower uric acid and homocysteine levels. In contrast, women did not demonstrate any significant variables associated with uric acid and homocysteine levels in each genotype.

Associations of polymorphism genotypes with LDL-C/HDL-C ratios and homocysteine levels
--------------------------------------------------------------------------------------

[Table 5](#t5){ref-type="table"} shows the proportion of participants with LDL-C/HDL-C ratios ≤2.0 and those \>2.0, according to the polymorphism genotypes. For the logistic regression analysis, the major homozygous genotypes were used as the reference group and the heterozygous and minor homozygous genotypes were used as the exposed group in the dominant model. When we combined the TC and CC genotypes for rs1165196 as the low-risk genotype comparison group (assuming a dominant effect for the variant C allele), the combined genotype (TC + CC) in men was associated with a significantly lower proportion of participants with an LDL-C/HDL-C ratio of \>2.0 (OR, 0.703; 95% CI, 0.536--0.922; OR adjusted for age, body mass index \[BMI\], research area, alcohol consumption and smoking habits, 0.642; 95% CI, 0.483--0.853), relative to the TT genotype. The combined genotype (CT + TT) in rs3757131 was also associated with a significantly lower proportion of participants with an LDL-C/HDL-C ratio \>2.0 (OR, 0.658; 95% CI, 0.500--0.866; OR adjusted for age, BMI, research area, alcohol consumption and smoking habits, 0.607; 95% CI, 0.455--0.808), relative to the major homozygous alleles. When we compared the rs1165196 and rs3757131 alleles in men using an LDL-C/HDL-C ratio of \>2.0, rs1165196 had a significantly lower frequency of the C allele, whereas rs3757131 had a significantly lower frequency of the T allele (T vs. C alleles in rs1165196: OR, 0.726; 95% CI, 0.573--0.920; C vs. T alleles in rs3757131: OR, 0.689; 95% CI, 0.542--0.876). Furthermore, we found that physical activity and daily energy or nutritional intake did not affect the LDL-C/HDL-C ratio in rs1165196 or rs3757131. In contrast, the proportions of women with an LDL-C/HDL-C ratio of \>2.0 were not significantly different when the various polymorphism genotypes were compared.

Similar analyses were performed for homocysteine levels ([Table 6](#t6){ref-type="table"}). In men, when we compared the alleles for rs1165196 and rs3757131 using homocysteine levels of \>10.0 nmol/mL, rs1165196 had a significantly lower frequency of the C allele, whereas rs3757131 had a significantly lower frequency of the T allele (T vs. C alleles in rs1165196: OR, 0.589; 95% CI, 0.420--0.826; C vs. T alleles in rs3757131: OR, 0.564; 95% CI, 0.399--0.797). Moreover, we confirmed that the tendency attenuated the relationship between hyperhomocysteinaemia and the *SLC17A1* polymorphisms, after adjusting for folic acid levels. In contrast, the proportion of women with homocysteine levels \>10.0 nmol/mL were not significantly different when we compared the various polymorphism genotypes.

Discussion
==========

High levels of uric acid are historically associated with gout, although recent studies have revealed that they might also be associated with cardiovascular disease and the incidence of coronary heart disease, hypertension, stroke, metabolic syndrome, and other disorders. Therefore, patients presenting with high uric acid levels should be screened and treated for comorbid cardiovascular risk factors[@b19]. Furthermore, a previous genome-wide association study of uric acid transporters revealed that several SNPs were significant genetic determinants of uric acid levels[@b20]. In that study, the *SLC17A1* polymorphisms exhibited an association with low serum levels of uric acid. The polymorphisms of interest for *SLC17A1* are rs1165196, rs1179086, and rs3757131; these polymorphisms are known to be associated with low levels of uric acid in Japanese men[@b18]. However, because these three SNPs exhibit strong linkage disequilibrium[@b18], determining which SNP is responsible for the functional changes in SLC17A1 is difficult. In agreement with these previous studies, our findings revealed significant associations between the *SLC17A1* polymorphisms and uric acid levels in Japanese men. Furthermore, in the present study, we also compared the associations between various *SLC17A1* genotypes and cardiovascular risk factors via altered cholesterol homeostasis and hyperhomocysteinaemia, after combining the heterozygous and minor homozygous alleles due to the small number of minor homozygotes. Our results indicated that, among male participants, the presence of minor alleles in rs1165196 and rs3757131 were associated with significantly lower homocysteine levels, compared to the major alleles. In addition, the odds of having a high LDL-C/HDL-C ratio or hyperhomocysteinaemia were significantly lower for patients with the minor alleles (vs. the major homozygous alleles), both before and after adjusting for age, BMI, research area, daily energy and nutritional intake, and alcohol consumption and smoking habits.

In healthy humans, uric acid is excreted in the urine, although kidney disease can impair this excretion route, leading to hyperuricaemia. In addition, hyperuricaemia can be caused by the increased generation of uric acid. Furthermore, exposure to lead or diets involving excessive intake of alcohol, purine nucleotides, protein, and carbohydrates can also contribute to high levels of uric acid[@b3]. However, in the present study, we found that alcohol consumption, physical activity, and daily energy or nutritional intake were not different for each SNP. Another potential mechanism leading to high uric acid levels is mutation(s) in the genes coding for the glucokinase regulatory protein; PDZ domain-containing proteins; and transporters of organic anions, glucose, ATP-binding cassettes, or monocarboxylic acid[@b15][@b20][@b21]; these transport proteins are key regulators of uric acid levels. Interestingly, *SLC17A1* is the gene involved in the renal transport of uric acid, and has been associated with low uric acid levels[@b18].

HDL-C is an undisputed and highly predictive biomarker of cardiovascular risk. In this context, HDL-C is central to reverse cholesterol transport, which is the cardioprotective mechanism by which cholesterol, synthesized in the peripheral tissues, is transported to the liver for degradation or recycling. Various factors can result in elevated HDL-C levels, including smoking, alcohol consumption, exercise, and statin therapy. However, epidemiological studies have demonstrated that uric acid levels are inversely correlated with HDL-C levels[@b22], and that there is a strong relationship between LDL-C levels and the incidence of atherosclerotic cardiovascular disease[@b10][@b23]. Another recent study has demonstrated that the LDL-C/HDL-C ratio is a precise marker of cholesterol homeostasis, and can be used to predict the risk of cardiovascular events[@b24]. Nicholls *et al.* showed that an LDL-C/HDL-C ratio \>2.0 was associated with plaque progression (despite statin usage), whereas a ratio \<1.5 was significantly associated with plaque regression[@b25]. Many studies have indicated that cholesterol homeostasis is a major mechanism for suppressing cardiovascular disease. In the present study, we used the LDL-C/HDL-C ratio to evaluate cholesterol homeostasis because it is a better predictor of future cardiovascular disease than are single lipid parameters (e.g., triglyceride, LDL-C, or HDL-C levels)[@b14]. However, we did not find a correlation between uric acid levels and cholesterol homeostasis for minor alleles in rs1165196 and rs3757131 (data not shown). These results suggest that the minor alleles in rs1165196 and rs3757131 had independent effects on uric acid levels and cholesterol homeostasis.

Various cardiovascular disease risk factors are reported to be related to homocysteine levels, including total cholesterol, other lipids, smoking, and the presence or absence of hypertension and diabetes mellitus. However, adjusting for these risk factors only weakly attenuates the strong relationship between homocysteine levels and mortality due to cardiovascular causes[@b5]. In addition, homocysteine levels are higher in patients with gout than in healthy controls, and uric acid levels are known to be correlated with homocysteine levels[@b22]. In contrast, hyperhomocysteinaemia is not correlated with uric acid levels in patients with gout, although there is an inverse association between homocysteine levels and renal function[@b26]. These reports indicate that hyperhomocysteinaemia, which may be related to uric acid levels and cardiovascular mortality, is clearly a cardiovascular risk factor, although the precise relationship remains unknown.

Interestingly, an association between hyperlipidaemia and hyperhomocysteinaemia has been suggested. In an animal model, hyperhomocysteinaemia inhibited reverse cholesterol transport by reducing circulating HDL levels, via inhibition of apoA-I protein synthesis, and enhanced HDL-C clearance[@b27]. Therefore, the liver may be a major organ involved in regulating homocysteine and cholesterol homeostasis[@b28]. These studies suggest that the interactions between homocysteine and HDL metabolism may be clinically important. Based on our findings, the rs1165196 and rs3757131 polymorphisms may be suitable biomarkers for cardiovascular disease risk factors, although their direct effect(s) on the metabolic pathway remains unknown.

Plasma homocysteine concentrations are typically considered to be inversely related to folic acid levels (a cofactor or substrate for enzymes involved in homocysteine metabolism). Similarly, a previous study reported that homocysteine levels in elderly Japanese individuals are inversely related to folic acid levels[@b29]. Furthermore, another study reported that folic acid supplementation lowered homocysteine levels, although the change in lipid metabolism was not significant at the end of the treatment period[@b28][@b30]. Nevertheless, the preventative effects of folic acid supplementation on cardiovascular disease cannot be excluded[@b31]. In the present study, high homocysteine and low folic acid levels were associated with the major homozygous alleles in rs1165196 and rs3757131. However, adjusting for folic acid weakly attenuated the relationship between hyperhomocysteinaemia and the *SLC17A1* polymorphisms. Nevertheless, the odds of hyperhomocysteinaemia were significantly different for rs1165196 and rs3757131, even after adjusting for folic acid levels. Therefore, *SLC17A1* polymorphisms appear to independently affect low homocysteine levels.

To the best of our knowledge, the present study was the first to explore the association between rs1165196 and rs3757131 genotypes and cardiovascular risk factors, altered cholesterol homeostasis, and homocysteine levels in Japanese men. However, in women, statistically significant differences in cholesterol homeostasis and homocysteine levels were not identified. Similarly, pronounced sex-related differences in the regulation of uric acid levels have been reported in both humans and animals[@b32]. In the Framingham Heart Study, the association between uric acid levels and mortality risk in men was not significant in the univariate analysis, and the association in women was not significant after adjusting for diuretic use, blood pressure, and total cholesterol levels[@b33]. Therefore, the specific physiological characteristics of women may be related to the sex-related differences in SNP genotypes that were observed to be associated with uric acid levels, although the underlying mechanism has yet to be elucidated. Furthermore, alcohol consumption, physical activity, and daily energy and nutrition intake did not affect the associations in either men or women. Therefore, identification of the pathogenic genetic factor(s) for cardiovascular disease remains critically important.

The limitations of our study include its cross-sectional design and the relatively small number of participants. Although a study with a low statistical power has a reduced likelihood of detecting a true effect, case-control studies with small sample sizes are still widely used, and can be used to assess previously identified candidate regions and more precisely determine target selections. In addition, we only assessed Japanese participants in the present study, and further studies in other ethnic groups are needed to validate our findings. Therefore, large, prospective trials involving patients from multiple ethnic groups are needed to better assess the effects of *SLC17A1* polymorphisms on cholesterol homeostasis and hyperhomocysteinaemia.

Conclusion
==========

In conclusion, our results indicate that the rs1165196 and rs3757131 polymorphisms, expressed in the liver, confer dominant negative effects on LDL-C/HDL-C ratios and hyperhomocysteinaemia in Japanese men. Although the exact biological mechanism for this association remains unknown, our findings provide credible evidence that the rs1165196 and rs3757131 polymorphisms may be associated with a decreased risk of cardiovascular disease. This risk reduction may be due to their important role in maintaining cholesterol homeostasis and preventing hyperhomocysteinaemia through altered liver function. However, further studies are needed to interpret the effects of *SLC17A1* polymorphisms on cardiovascular disease.

Methods
=======

Study participants
------------------

In the present study, we evaluated participant data collected during the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study. That cohort study evaluated the general Japanese population in 10 research areas, using genetic and clinical data to detect and confirm gene-environment interactions related to lifestyle-associated diseases[@b34]. The study participants were 35--69 years old, and were enrolled after responding to study announcements in their specific research areas, attending health check-up examinations that were commissioned by their local governments, visiting local health check-up centres, or visiting a cancer hospital. A total of 4490 participants were selected, with approximately 500--600 participants from each research area, except for two areas in which fewer participants were recruited[@b35].

Among these 4490 participants, 2035 were excluded because they had consumed a meal \<6 h before having their blood drawn, 228 because they were receiving cholesterol-lowering medication, 24 due to high triglyceride levels (≥400 mg/dL), 338 due to insufficient laboratory data, and 23 individuals were excluded due to the absence of other data. After these exclusions, 1842 individuals (995 men and 847 women) were eligible for analyses. Folic acid (751 men and 620 women) and homocysteine (719 men and 606 women) levels limited the number of participants.

All participants provided written informed consent for the J-MICC Study, and the main study protocol of the J-MICC Study was approved by Ethics Committee at Nagoya University School of Medicine (Approval number 253 and 939). Since actual studies are slightly different from the main J-MICC Study protocol, all procedures involved in this study were performed in accordance with the institutional ethical committees (Chiba Cancer Center, Nagoya University, Nagoya City University, Aichi Cancer Center, Shiga University of Medical Science, Kyoto Prefectural University of Medicine, Tokushima University, Kyushu University, Saga University, and Kagoshima University).

Blood biochemistry, lifestyle, and nutritional data
---------------------------------------------------

In the present study, we evaluated lifestyle and medical information obtained through self-administered questionnaires (alcohol consumption status \[0, 0.1--22.9, 23.0--45.9, or ≥46.0 g ethanol/day\], smoking habits, current medications, and exercise). In addition, blood chemistry data (serum levels of triglycerides, total cholesterol, HDL-C, uric acid, LDL-C \[calculated using the Friedewald formula[@b36], and plasma levels of homocysteine and folic acid) and anthropometric data were obtained from health check-ups performed in the research areas. Each blood sample was centrifuged and the plasma was separated and stored at --80 °C until analysis. Serum samples were measured by laboratories in each research area. Plasma folic acid concentrations were measured using a chemiluminescent enzyme immunoassay, and plasma homocysteine concentrations were measured using high-performance liquid chromatography by a contract laboratory (SRL, Tokyo, Japan).

For the dietary assessment, a validated food-frequency questionnaire was used to evaluate the intake frequency of 47 foods and beverages over the preceding year, and the total daily energy (kcal), protein (g), fat (g), and carbohydrate (g) intakes were calculated[@b37][@b38][@b39][@b40]. Physical activity was assessed as METs for daily and leisure activities, as previously reported[@b41]. In brief, METs-hours per day (METs·h/day) of daily activity were estimated for heavy physical work and walking. For leisure activities, METs·h/day were estimated by multiplying the reported daily time spent in each activity by the relevant MET intensity.

Genotyping *SLC17A1* polymorphisms
----------------------------------

Our previous study described the details of the genetic analysis[@b35]. Briefly, genomic DNA was extracted from the buffy coat fraction of the participant's blood sample, using a BioRobot M48 Workstation (QIAGEN Group, Tokyo, Japan). The *SLC17A1* polymorphisms (rs1165196, rs1179086, and rs3757131) were genotyped using a multiplex polymerase chain reaction-based Invader assay (Third Wave Technologies, Madison, WI, USA) at the RIKEN Laboratory for Genotyping Development, Center for Genomic Medicine (Yokohama, Japan)[@b42]. The rs1165196 polymorphism is located at exon 7, where a conversion from thymine to cytosine at nucleotide 806 results in the substitution of threonine for isoleucine. The rs1179086 and rs3757131 polymorphisms are located at intron 12[@b18].

Statistical analyses
--------------------

Inter-group comparisons were performed using Student's unpaired *t-*tests for continuous variables and chi-square tests for categorical variables (alcohol consumption in current drinkers, smokers, and allele independence \[Hardy-Weinberg equilibrium\]). Differences in quantitative data, between the genotypes, were evaluated using one-way analysis of variance. All data were expressed as means ± standard deviation, or as indicated, and the coefficients of variation (CVs) for each parameter were calculated. ORs, 95% CIs, and p-values were calculated using logistic regression analyses; the LDL-C/HDL-C ratio (\>2.0) was defined as the dependent variable, and participant age, sex, BMI (kg/m^2^), research area, METs, daily energy and nutritional intake (protein, fat, and carbohydrate), and alcohol consumption and smoking habits, were included as independent variables. In the general Japanese population, a plasma homocysteine concentration of \>10.0 nmol/mL is defined as hyperhomocysteinaemia[@b29], and this cut-off value was used for our analyses. We performed logistic regression analyses with the homocysteine level defined as the dependent variable, and patient age, sex, BMI, research area, folic acid level, and alcohol consumption and smoking habits were included as independent variables. All statistical tests were two-sided, and differences with a p-value of \<0.05 were considered statistically significant. SPSS software (version 18.0, SPSS, Japan, Inc.) was used for all statistical analyses.
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###### Clinical characteristics and genotype frequencies of the participants, according to sex.

                                                          Men (n = 995)  Women (n = 847)                         
  ------------------------------------------------------ --------------- ----------------- -------------- ------ ---------
  Age (years)                                              55.6 ± 8.8    15.8                54.8 ± 8.5   15.5     0.052
  BMI (kg/m^2^)                                            23.8 ± 3.1    13.0                22.9 ± 3.3   14.4    \<0.001
  Triglycerides (mg/dL)                                   120.7 ± 61.0   50.5               92.2 ± 49.3   53.4    \<0.001
  Total cholesterol (mg/dL)                               204.3 ± 31.4   15.3               216.9 ± 35.4  16.3    \<0.001
  LDL-C (mg/dL)                                           120.6 ± 29.7   24.6               129.5 ± 33.7  26.0    \<0.001
  HDL-C (mg/dL)                                            59.5 ± 15.7   26.3               68.9 ± 15.2   22.0    \<0.001
  LDL-C/HDL-C                                              2.17 ± 0.78   35.9               2.00 ± 0.77   38.5    \<0.001
  Uric acid (mg/dL)                                        6.03 ± 1.17   19.4               4.43 ± 0.99   22.3    \<0.001
  Folic acid (ng/mL)[\*](#t1-fn1){ref-type="fn"}           8.61 ± 2.25   26.1               9.75 ± 3.26   33.4    \<0.001
  Homocysteine (nmol/mL)[\*\*](#t1-fn1){ref-type="fn"}     9.37 ± 3.48   37.1               7.36 ± 2.51   34.1    \<0.001
  Energy intake (kcal/day)                                 1,930 ± 360   18.6               1,547 ± 251   16.2    \<0.001
  Protein intake (g/day)                                   55.8 ± 11.2   20.0               51.3 ± 10.5   20.4    \<0.001
  Fat intake (g/day)                                       41.8 ± 10.5   25.1               44.6 ± 11.7   26.2    \<0.001
  Carbohydrate intake (g/day)                             278.6 ± 70.3   25.2               216.4 ± 45.1  20.8    \<0.001
  METs (h/day)                                             14.7 ± 14.0   95.2               15.0 ± 13.7   91.3     0.693
  Alcohol drinking                                                                                               
   0 g/d                                                   393 (39.4)                        593 (70.0)               
   0.1--22.9 g/d                                           414 (41.6)    238 (28.0)           \<0.001            
   23.0--45.9 g/d                                          122 (12.2)    15 (1.77)                               
   ≥46.0 g/d                                                66 (6.63)    1 (0.11)                                
  Smoking                                                                                                        
   Current                                                 272 (27.3)                        45 (5.31)            \<0.001
   Former                                                  433 (43.5)    25 (2.95)                               
   Never                                                   290 (29.1)    777 (91.7)                              
  rs1165196                                                                                                      
   TT                                                      694 (69.7)                        612 (72.2)            0.496
   TC                                                      271 (27.2)    211 (24.9)                              
   CC                                                       30 (3.01)    24 (2.83)                               
  rs1179086                                                                                                      
   AA                                                      542 (54.4)                        467 (55.1)            0.634
   AT                                                      386 (38.7)    315 (37.1)                              
   TT                                                       67 (6.73)    65 (7.67)                               
  rs3757131                                                                                                      
   CC                                                      703 (70.6)                        610 (72.0)            0.795
   CT                                                      264 (26.5)    213 (25.1)                              
   TT                                                       28 (2.81)    24 (2.83)                               

Data are means ± standard deviation.

CV, coefficient of variance BMI, body mass index; LDL-C, low-density lipoprotein cholesterol.

HDL-C, high-density lipoprotein cholesterol; METs, metabolic equivalents.

Sex-related differences were analysed using the *t*-test,

Chi-square tests were used for smoking and alcohol habits and genotypes.

^\*^Men = 751, Women = 620, \*\*Men = 719, Women = 606.

###### The distribution of the participants, according to sex, for rs1165196.

  Sex                                                    Men            Women                                                                                                                              
  ------------------------------------------------------ -------------- -------------- -------------- ------- -------------- --------- -------------- -------------- -------------- ------- -------------- -------
  Age (years)                                            55.5 ± 8.8     55.5 ± 8.9     58.2 ± 7.9     0.271   55.7 ± 8.8     0.730     54.7 ± 8.7     54.8 ± 8.1     58.2 ± 7.0     0.131   55.1 ± 8.1     0.491
  BMI (kg/m^2^)                                          23.7 ± 3.0     24.1 ± 3.1     23.7 ± 2.9     0.145   24.1 ± 3.1     0.062     22.9 ± 3.3     22.7 ± 3.2     23.5 ± 4.1     0.483   22.8 ± 3.3     0.570
  Triglycerides (mg/dL)                                  120.6 ± 59.4   121.8 ± 64.9   112.8 ± 64.2   0.741   120.9 ± 64.8   0.946     93.4 ± 50.0    88.3 ± 45.8    94.0 ± 59.5    0.433   88.9 ± 47.3    0.238
  Total cholesterol (mg/dL)                              204.2 ± 31.4   204.0 ± 31.5   211.0 ± 32.1   0.503   204.7 ± 31.6   0.818     217.7 ± 35.1   214.0 ± 36.9   222.0 ± 27.1   0.324   214.8 ± 36.0   0.287
  LDL-C (mg/dL)                                          121.1 ± 29.9   119.3 ± 29.2   121.5 ± 30.0   0.690   119.5 ± 29.2   0.441     129.8 ± 33.1   128.1 ± 36.0   133.8 ± 27.1   0.668   128.7 ± 35.2   0.665
  HDL-C (mg/dL)                                          58.9 ± 15.5    60.3 ± 16.0    66.8 ± 14.3    0.017   60.9 ± 16.0    0.062     69.1 ± 15.4    68.1 ± 15.0    69.4 ± 11.4    0.705   68.3 ± 14.6    0.454
  LDL-C/HDL-C                                            2.20 ± 0.79    2.12 ± 0.75    1.92 ± 0.71    0.069   2.10 ± 0.75    0.053     2.00 ± 0.77    2.00 ± 0.81    1.99 ± 0.58    0.999   2.00 ± 0.79    0.977
  Uric acid (mg/dL)                                      6.10 ± 1.14    5.87 ± 1.21    5.94 ± 1.40    0.020   5.88 ± 1.23    0.005     4.49 ± 1.00    4.27 ± 0.92    4.28 ± 1.22    0.016   4.27 ± 0.95    0.004
  Folic acid (ng/mL)[\*](#t2-fn1){ref-type="fn"}         8.42 ± 2.13    8.98 ± 2.51    9.69 ± 1.80    0.001   9.04 ± 2.46    0.001     9.71 ± 3.08    9.84 ± 3.74    9.84 ± 2.97    0.912   9.84 ± 3.66    0.667
  Homocysteine (nmol/mL)[\*\*](#t2-fn1){ref-type="fn"}   9.66 ± 3.85    8.70 ± 2.34    8.51 ± 1.53    0.003   8.69 ± 2.29    \<0.001   7.36 ± 2.72    7.38 ± 1.92    7.20 ± 1.92    0.957   7.36 ± 1.91    0.982
  Energy intake (kcal/day)                               1,929 ± 356    1,933 ± 376    1,919 ± 284    0.976   1,931 ± 367    0.925     1,546 ± 248    1,552 ± 257    1,542 ± 267    0.957   1,551 ± 258    0.813
  Protein intake (g/day)                                 56.0 ± 11.4    55.2 ± 11.0    55.1 ± 9.52    0.587   55.2 ± 10.9    0.303     51.4 ± 10.6    51.4 ± 10.3    50.2 ± 12.3    0.866   51.3 ± 10.5    0.893
  Fat intake (g/day)                                     41.9 ± 10.8    41.4 ± 9.89    43.1 ± 8.78    0.654   41.6 ± 9.78    0.676     44.5 ± 11.7    45.0 ± 11.7    45.1 ± 11.8    0.830   45.0 ± 11.7    0.542
  Carbohydrate intake (g/day)                            279.0 ± 71.1   278.8 ± 69.8   267.8 ± 56.8   0.695   277.7 ± 68.6   0.797     215.9 ± 43.9   218.6 ± 47.4   211.1 ± 56.6   0.630   217.9 ± 48.3   0.565
  METs (h/day)                                           14.9 ± 14.1    14.4 ± 14.5    13.7 ± 8.7     0.847   14.4 ± 14.0    0.606     15.0 ± 13.5    15.2 ± 14.3    13.2 ± 11.4    0.790   15.0 ± 14.1    0.976

Data are presented as means ± standard deviation; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; METs, metabolic equivalents.

Genotype differences were analysed using one-way analysis of variance^\*^, or the *t*-test^\*\*^

^\*^Men (TT = 524, TC = 208, CC = 19) Women (TT= 439, TC = 161, CC = 20).

^\*\*^Men (TT = 502, TC = 201, CC = 16) Women (TT = 431, TC = 156, CC = 19).

###### The distribution of participants, according to sex, for rs1179086.

  Sex                                                    Men            Women                                                                                                                            
  ------------------------------------------------------ -------------- -------------- -------------- ------- -------------- ------- -------------- -------------- -------------- ------- -------------- -------
  Age (years)                                            55.3 ± 8.9     55.7 ± 8.8     56.5 ± 8.3     0.537   55.9 ± 8.7     0.371   55.1 ± 8.5     54.5 ± 8.4     54.0 ± 8.9     0.501   54.4 ± 8.5     0.289
  BMI (kg/m^2^)                                          23.6 ± 2.9     24.0 ± 3.2     23.7 ± 2.9     0.161   24.0 ± 3.2     0.086   22.9 ± 3.3     22.8 ± 3.3     23.1 ± 3.4     0.844   22.9 ± 3.3     0.850
  Triglycerides (mg/dL)                                  118.3 ± 58.4   125.2 ± 64.7   114.6 ± 59.6   0.168   123.6 ± 64.0   0.175   94.7 ± 52.4    87.5 ± 41.7    96.6 ± 58.6    0.099   89.0 ± 45.1    0.096
  Total cholesterol (mg/dL)                              204.0 ± 30.9   203.9 ± 31.8   209.1 ± 33.4   0.438   204.7 ± 32.1   0.741   218.7 ± 35.5   214.8 ± 35.7   214.2 ± 32.9   0.258   214.7 ± 35.2   0.101
  LDL-C (mg/dL)                                          121.0 ± 29.2   119.8 ± 30.2   122.1 ± 31.2   0.769   120.2 ± 30.3   0.662   130.2 ± 33.4   129.2 ± 34.5   125.7 ± 32.2   0.599   128.6 ± 34.1   0.501
  HDL-C (mg/dL)                                          59.3 ± 15.7    59.0 ± 15.8    64.0 ± 14.3    0.049   59.7 ± 15.7    0.662   69.5 ± 15.8    68.0 ± 14.5    69.0 ± 14.3    0.403   68.2 ± 14.4    0.212
  LDL-C/HDL-C                                            2.19 ± 0.79    2.17 ± 0.78    2.00 ± 0.70    0.198   2.15 ± 0.77    0.417   1.99 ± 0.78    2.01 ± 0.78    1.93 ± 0.72    0.721   2.00 ± 0.77    0.964
  Uric acid (mg/dL)                                      6.13 ± 1.18    5.94 ± 1.14    5.83 ± 1.26    0.016   5.92 ± 1.16    0.005   4.53 ± 0.98    4.31 ± 0.97    4.23 ± 1.04    0.002   4.30 ± 0.98    0.001
  Folic acid (ng/mL)                                     8.44 ± 2.16    8.79 ± 2.39    9.05 ± 1.95    0.054   8.82 ± 2.34    0.021   9.78 ± 3.24    9.76 ± 3.37    9.53 ± 2.78    0.888   9.72 ± 3.28    0.838
  Homocysteine (nmol/mL)[\*\*](#t3-fn1){ref-type="fn"}   9.53 ± 3.92    9.23 ± 2.95    8.63 ± 1.79    0.217   9.16 ± 2.83    0.156   7.19 ± 2.16    7.50 ± 2.98    7.86 ± 2.29    0.142   7.56 ± 2.88    0.076
  Energy intake (kcal/day)                               1,938 ± 350    1,921 ± 381    1,908 ± 308    0.687   1,919 ± 371    0.413   1,553 ± 253    1,543 ± 251    1,530 ± 241    0.740   1,541 ± 249    0.494
  Protein intake (g/day)                                 56.1 ± 11.2    55.5 ± 11.4    54.4 ± 10.1    0.407   55.3 ± 11.2    0.272   51.4 ± 10.2    51.5 ± 10.9    50.4 ± 11.3    0.748   51.3 ± 11.0    0.884
  Fat intake (g/day)                                     41.8 ± 10.8    41.6 ± 9.94    42.3 ± 11.1    0.881   41.7 ± 10.1    0.891   44.3 ± 11.1    45.0 ± 12.1    45.9 ± 13.9    0.490   45.1 ± 12.4    0.290
  Carbohydrate intake (g/day)                            282.4 ± 69.7   274.8 ± 72.9   269.6 ± 57.6   0.152   274.1 ± 70.9   0.063   216.8 ± 44.8   216.7 ± 45.1   212.2 ± 48.6   0.728   216.0 ± 45.7   0.777
  METs (h/day)                                           14.8 ± 13.7    14.5 ± 14.9    15.3 ± 12.3    0.899   14.6 ± 14.5    0.844   14.6 ± 13.2    15.3 ± 14.4    16.0 ± 13.9    0.596   15.5 ± 14.3    0.342

Data are presented as means ± standard deviation; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; METs, metabolic equivalents.

Genotype differences were analysed using one-way analysis of variance^\*^, or the *t*-test^\*\*^.

^\*^Men (TT = 412, TC = 294, CC = 45) Women (TT = 335, TC = 237, CC = 48).

^\*\*^Men (TT = 399, TC = 281, CC = 39) Women (TT = 330, TC = 231, CC = 65).

###### The distribution of the participants, according to sex, for rs3757131.

  Sex                                                    Men            Women                                                                                                                              
  ------------------------------------------------------ -------------- -------------- -------------- ------- -------------- --------- -------------- -------------- -------------- ------- -------------- -------
  Age (years)                                            55.5 ± 8.8     55.4 ± 8.9     58.0 ± 7.9     0.342   55.7 ± 8.8     0.808     54.7 ± 8.7     54.9 ± 8.0     57.5 ± 7.7     0.293   55.1 ± 8.0     0.496
  BMI (kg/m^2^)                                          23.7 ± 3.0     24.1 ± 3.2     23.6 ± 2.6     0.155   24.0 ± 3.1     0.073     22.9 ± 3.3     22.7 ± 3.2     23.3 ± 4.0     0.630   22.8 ± 3.3     0.570
  Triglycerides (mg/dL)                                  120.6 ± 59.2   122.0 ± 65.6   111.9 ± 64.0   0.708   121.0 ± 65.4   0.932     93.1 ± 49.6    89.3 ± 47.3    94.1 ± 59.4    0.628   89.8 ± 48.5    0.394
  Total cholesterol (mg/dL)                              203.9 ± 31.4   204.6 ± 31.4   212.2 ± 32.8   0.391   205.3 ± 31.6   0.536     217.8 ± 35.1   213.8 ± 37.0   220.7 ± 27.7   0.310   214.5 ± 36.2   0.219
  LDL-C (mg/dL)                                          121.0 ± 29.8   119.3 ± 29.3   122.7 ± 30.6   0.673   119.6 ± 29.4   0.501     129.9 ± 33.2   128.0 ± 35.9   131.1 ± 28.6   0.749   128.3 ± 35.2   0.530
  HDL-C (mg/dL)                                          58.7 ± 15.4    60.8 ± 16.3    67.0 ± 14.2    0.007   61.4 ± 16.2    0.014     69.2 ± 15.4    67.8 ± 14.8    70.7 ± 12.7    0.449   68.1 ± 14.6    0.362
  LDL-C/HDL-C                                            2.20 ± 0.79    2.10 ± 0.76    1.94 ± 0.73    0.058   2.09 ± 0.76    0.032     2.00 ± 0.77    2.00 ± 0.80    1.93 ± 0.62    0.919   1.99 ± 0.79    0.962
  Uric acid (mg/dL)                                      6.10 ± 1.15    5.86 ± 1.21    5.95 ± 1.42    0.015   5.87 ± 1.23    0.004     4.48 ± 1.00    4.29 ± 0.92    4.19 ± 1.19    0.029   4.28 ± 0.95    0.009
  Folic acid (ng/mL)                                     8.43 ± 2.12    9.00 ± 2.52    9.72 ± 1.85    0.001   9.05 ± 2.48    \<0.001   9.70 ± 3.08    9.88 ± 3.74    9.71 ± 2.86    0.830   9.86 ± 3.65    0.572
  Homocysteine (nmol/mL)[\*\*](#t4-fn2){ref-type="fn"}   9.67 ± 3.84    8.63 ± 2.29    8.60 ± 1.60    0.001   8.63 ± 2.25    \<0.001   7.38 ± 2.73    7.34 ± 1.92    7.18 ± 1.93    0.940   7.32 ± 1.91    0.803
  Energy intake (kcal/day)                               1,928 ± 355    1,934 ± 379    1,923 ± 294    0.973   1,933 ± 372    0.854     1,546 ± 247    1,550 ± 260    1,553 ± 267    0.979   1,550 ± 260    0.843
  Protein intake (g/day)                                 56.0 ± 11.4    55.2 ± 11.0    55.0 ± 9.86    0.586   55.2 ± 10.9    0.303     51.3 ± 10.5    51.4 ± 10.4    50.5 ± 12.3    0.918   51.3 ± 10.6    0.957
  Fat intake (g/day)                                     41.8 ± 10.8    41.6 ± 9.81    42.6 ± 8.92    0.891   41.7 ± 9.71    0.918     44.5 ± 11.7    45.0 ± 11.7    46.0 ± 11.6    0.720   45.1 ± 11.7    0.483
  Carbohydrate intake (g/day)                            279.2 ± 70.6   278.2 ± 70.8   268.1 ± 58.8   0.711   277.2 ± 69.7   0.683     216.1 ± 43.7   217.9 ± 47.9   212.3 ± 56.8   0.794   217.3 ± 48.8   0.718
  METs (h/day)                                           14.9 ± 14.2    14.2 ± 14.1    13.1 ± 8.82    0.649   14.1 ± 13.6    0.396     14.9 ± 13.5    15.4 ± 14.4    12.8 ± 11.5    0.669   15.1 ± 14.1    0.840

Data are presented as means ± standard deviation; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; METs, metabolic equivalents.

Genotype differences were analysed using one-way analysis of variance^\*^, or the *t*-test^\*\*^.

^\*^Men (TT = 530, TC = 204, CC = 17) Women (TT = 435, TC = 165, CC = 20).

^\*\*^Men (TT = 507, TC = 198, CC = 14) Women (TT = 427, TC = 160, CC = 19).

###### Associations between the SLC17A1 gene variants and the LDL-C/HDL-C ratio.

  SNP/genotype    Men   Women                                                                                                                                                                 
  -------------- ----- ------- ----------- -------------- ----------- -------------- ----------- -------------- ----- ----- ----------- -------------- ----------- -------------- ----------- --------------
  rs1165196                                                                                                                                                                                   
   TT             292    402    Reference                  Reference                  Reference                  336   276   Reference                  Reference                  Reference         
   TC             136    135      0.721     0.544--0.956     0.653     0.486--0.878     0.649     0.481--0.877   124   87      0.854     0.622--1.173     0.844     0.594--1.198     0.846     0.595--1.204
   CC             17     13       0.555     0.266--1.162     0.549     0.253--1.191     0.572     0.261--1.253   12    12      1.217     0.538--2.753     0.920     0.376--2.251     0.978     0.399--2.401
   TC+CC          153    148      0.703     0.536--0.922     0.642     0.483--0.853     0.642     0.481--0.857   136   99      0.886     0.654--1.201     0.845     0.604--1.183     0.853     0.609--1.195
   T              720    939    Reference                  Reference                  Reference                  796   639   Reference                  Reference                  Reference         
   C              170    161      0.726     0.573--0.920     0.679     0.531--0.869     0.684     0.533--0.878   148   111     0.934     0.715--1.220     0.869     0.647--1.167     0.877     0.653--1.179
  rs1179086                                                                                                                                                                                   
   AA             234    308    Reference                  Reference                  Reference                  256   211   Reference                  Reference                  Reference         
   AT             175    211      0.916     0.704--1.191     0.866     0.657--1.143     0.884     0.666--1.172   177   138     0.946     0.709--1.261     0.898     0.652--1.237     0.894     0.647--1.234
   TT             36     31       0.654     0.393--1.089     0.671     0.391--1.152     0.689     0.399--1.190   39    26      0.809     0.477--1.372     0.677     0.375--1.222     0.668     0.369--1.209
   AT+TT          211    242      0.871     0.678--1.120     0.828     0.636--1.078     0.686     0.646--1.106   216   164     0.921     0.701--1.210     0.861     0.635--1.167     0.860     0.633--1.169
   A              643    827    Reference                  Reference                  Reference                  689   560   Reference                  Reference                  Reference         
   T              247    273      0.859     0.703--1.050     0.835     0.677--1.029     0.849     0.686--1.050   255   190     0.917     0.737--1.141     0.855     0.671--1.090     0.857     0.672--1.093
  rs3757131                                                                                                                                                                                   
   CC             293    410    Reference                  Reference                  Reference                  334   276   Reference                  Reference                  Reference         
   CT             136    128      0.673     0.506--0.894     0.614     0.456--0.828     0.614     0.453--0.832   125   88      0.852     0.621--1.168     0.842     0.594--1.194     0.845     0.595--1.201
   TT             16     12       0.536     0.250--1.150     0.537     0.242--1.189     0.563     0.251--1.265   13    11      1.024     0.452--2.322     0.782     0.320--1.909     0.823     0.335--2.021
   CT+TT          152    140      0.658     0.500--0.866     0.607     0.455--0.808     0.609     0.455--0.816   138   99      0.868     0.641--1.176     0.831     0.594--1.162     0.839     0.599--1.175
   C              722    948    Reference                  Reference                  Reference                  793   640   Reference                  Reference                  Reference         
   T              168    152      0.689     0.542--0.876     0.649     0.506--0.833     0.656     0.509--0.846   151   110     0.903     0.691--1.179     0.844     0.629--1.133     0.853     0.635--1.146

SNP, single nucleotide polymorphism; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; OR, odds ratio; CI, confidence interval.

^†^Adjusted for age, body mass index, research area, alcohol consumption, smoking habits.

^‡^Adjusted for age, body mass index, research area, METs, daily energy and nutritional intake (protein, fat, carbohydrate), and alcohol and smoking habits.

###### Associations between the SLC17A1 gene variants and hyperhomocysteinaemia.

  SNP/genotype    Men   Women                                                                                                                                                                 
  -------------- ----- ------- ----------- -------------- ----------- -------------- ----------- -------------- ----- ----- ----------- -------------- ----------- -------------- ----------- --------------
  rs1165196                                                                                                                                                                                   
   TT             336    166    Reference                  Reference                  Reference                  387   44    Reference                  Reference                  Reference         
   TC             158    43       0.551     0.375--0.810     0.505     0.340--0.751     0.560     0.371--0.844   141   15      0.936     0.505--1.734     0.923     0.492--1.731     0.942     0.498--1.781
   CC             13      3       0.467     0.131--1.662     0.447     0.122--1.634     0.542     0.143--2.047   17     2      1.035     0.231--4.628     0.792     0.169--3.704     0.796     0.166--3.814
   TC+CC          171    46       0.544     0.374--0.792     0.499     0.339--0.734     0.560     0.375--0.835   158   17      0.946     0.525--1.706     0.910     0.498--1.663     0.927     0.504--1.707
   T              830    375    Reference                  Reference                  Reference                  915   103   Reference                  Reference                  Reference         
   C              184    49       0.589     0.420--0.826     0.550     0.389--0.777     0.609     0.426--0.870   175   19      0.964     0.576--1.615     0.910     0.537--1.540     0.923     0.542--1.572
  rs1179086                                                                                                                                                                                   
   AA             273    126    Reference                  Reference                  Reference                  300   30    Reference                  Reference                  Reference         
   AT             202    79       0.847     0.606--1.185     0.788     0.557--1.113     0.854     0.595--1.227   208   23      1.106     0.625--1.958     1.028     0.571--1.851     1.041     0.574--1.888
   TT             32      7       0.474     0.204--1.103     0.431     0.181--1.022     0.468     0.192--1.137   37     8      2.162     0.923--5.066     1.868     0.763--4.574     1.883     0.751--4.723
   AT+TT          234    86       0.796     0.575--1.102     0.733     0.524--1.027     0.796     0.560--1.131   245   31      1.265     0.745--2.149     1.164     0.675--2.007     1.175     0.677--2.041
   A              748    331    Reference                  Reference                  Reference                  808   83    Reference                  Reference                  Reference         
   T              266    93       0.790     0.604--1.034     0.743     0.564--0.980     0.788     0.591--1.050   282   39      1.346     0.899--2.016     1.258     0.831--1.904     1.264     0.830--1.925
  rs3757131                                                                                                                                                                                   
   CC             338    169    Reference                  Reference                  Reference                  383   44    Reference                  Reference                  Reference         
   CT             158    40       0.506     0.342--0.750     0.466     0.311--0.698     0.514     0.338--0.781   145   15      0.900     0.486--1.668     0.902     0.481--1.691     0.926     0.490--1.750
   TT             11      3       0.545     0.150--1.981     0.536     0.144--1.997     0.665     0.171--2.584   17     2      1.024     0.229--4.580     0.763     0.163--3.569     0.763     0.160--3.467
   CT+TT          169    43       0.509     0.347--0.746     0.468     0.316--0.694     0.523     0.348--0.786   162   17      0.913     0.507--1.646     0.890     0.487--1.625     0.910     0.495--1.674
   C              834    378    Reference                  Reference                  Reference                  911   103   Reference                  Reference                  Reference         
   T              180    46       0.564     0.399--0.797     0.529     0.371--0.754     0.585     0.406--0.843   179   19      0.939     0.561--1.571     0.893     0.528--1.510     0.907     0.532--1.544

SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

^†^Adjusted for age, body mass index, research area, alcohol consumption, smoking habits.

^‡^Adjusted for age, body mass index, research area, folic acid, alcohol consumption, smoking habits.
